BA (Biology): Harvard University; Cambridge, MA; 1996
MD (Medicine): University of California at San Francisco; San Francisco, CA; 2001
Internship/Residency (Internal Medicine): Yale-New Haven Hospital; New Haven, CT; 2005
Medical Fellowship: Yale University School of Medicine; New Haven, CT; 2008
Postdoctoral Fellowship: University of Pennsylvania School of Medicine; Philadelphia, PA; 2009
Dr. Cheng is a pulmonologist and critical care specialist who sees patients at the SCCA who have pulmonary complications after hematopoietic stem cell transplantation (HCT), including infectious pneumonia and non-infectious pulmonary complications. She also performs bronchoscopies for the diagnosis of respiratory infections as well as early detection of lung cancer and other pulmonary conditions.
She has authored two chapters about mediastinal disease for the Textbook of Respiratory Medicine, the definitive text on pulmonary disorders.
Dr. Cheng is focused on improving outcomes for stem cell transplant patients with respiratory failure that today can lead to early mortality. She has studied the role that respiratory viruses can play in non-infectious pulmonary complications in this immunocompromised population. Dr. Cheng is developing novel diagnostic and therapeutic approaches that might prevent lung damage or improve lung function after failure. She is also advancing diagnostic strategies for early detection of lung cancer.
Her primary interest is bronchiolitis obliterans syndrome (BOS), which is a relatively rare but serious HCT complication that can lead to early mortality. Currently, there are no therapies that routinely reverse the course of the disease, and Dr. Cheng is working to develop early detection and prevention strategies for HCT patients, and for lung transplant recipients who can also suffer BOS. She was recently involved in an NIH-sponsored clinical trial of a new treatment for BOS, which had promising results in the majority of new-onset BOS patients.